ORYZON Raises $19 Million in Private Placement to Advance Therapeutic Programs
- 4.9 million new shares issued at a price of 3.39 euros per share
- The company is valued at $110 million
- The new shareholders include CEO of Active Motif, a US epigenetics company, also a founder of Invitrogen
- The Company expects to list on the Madrid Stock Exchange before year-end
BARCELONA / CAMBRIDGE, MA
The General Meeting of Shareholders of Oryzon, a clinical stage biopharmaceutical company focused on Epigenetics to develop therapies in oncology and neurodegenerative diseases, agreed to publicly trade 100% of the company’s shares in the Spanish Main Market.